SCHEMBL23577166

SCHEMBL23577166

CN(c1cccc(-c2ccc(C(C)(C)C)cc2)c1)c1nc2nncn2c2cc(Cl)c(F)cc12

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.33
DHODH Q02127 1/20 0.31
OPRD1 P41143 1/20 0.31
ICMT O60725 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909794 1.00 FNTA (0.34) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL23601029 0.93 FNTA (0.34) FNTAFNTBABCG2DHODH
SCHEMBL29909506 0.93 ABCG2 (0.35) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL23577238 0.93 ABCG2 (0.35) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL29909455 0.89 ABCG2 (0.33) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL23577282 0.89 ABCG2 (0.33) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL23577223 0.87 DHODH (0.33) FNTAFNTBABCG2DHODH
SCHEMBL23577367 0.87 ABCG2 (0.33) FNTAFNTBABCG2DHODHOPRD1
SCHEMBL23576894 0.87 SCN9A (0.34) FNTAFNTBABCG2
SCHEMBL29909614 0.87 DHODH (0.33) FNTAFNTBABCG2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885ABCG2 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.